INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,693,399 | +581.4% | 576,774 | +306.5% | 0.00% | – |
| Q2 2023 | $1,569,438 | -68.2% | 141,902 | -61.4% | 0.00% | -100.0% |
| Q1 2023 | $4,939,298 | -48.3% | 367,781 | -52.4% | 0.00% | 0.0% |
| Q4 2022 | $9,554,340 | -23.7% | 772,380 | -14.0% | 0.00% | -50.0% |
| Q3 2022 | $12,527,000 | -14.5% | 897,973 | -15.4% | 0.00% | 0.0% |
| Q2 2022 | $14,655,000 | +59.0% | 1,061,169 | +87.3% | 0.00% | +100.0% |
| Q1 2022 | $9,217,000 | +191.7% | 566,492 | +192.1% | 0.00% | – |
| Q4 2021 | $3,160,000 | +23.3% | 193,965 | +12.3% | 0.00% | – |
| Q3 2021 | $2,563,000 | -77.7% | 172,676 | -70.0% | 0.00% | -100.0% |
| Q2 2021 | $11,480,000 | +209.5% | 574,811 | +257.6% | 0.00% | +100.0% |
| Q1 2021 | $3,709,000 | -50.7% | 160,721 | -47.2% | 0.00% | 0.0% |
| Q4 2020 | $7,521,000 | +215.9% | 304,497 | +430.2% | 0.00% | – |
| Q3 2020 | $2,381,000 | -11.0% | 57,432 | +2.8% | 0.00% | -100.0% |
| Q2 2020 | $2,676,000 | -33.2% | 55,869 | -12.1% | 0.00% | 0.0% |
| Q1 2020 | $4,003,000 | -55.2% | 63,571 | -11.9% | 0.00% | -50.0% |
| Q4 2019 | $8,942,000 | +194.1% | 72,156 | +57.5% | 0.00% | +100.0% |
| Q3 2019 | $3,040,000 | -12.3% | 45,817 | +5.2% | 0.00% | 0.0% |
| Q2 2019 | $3,467,000 | -25.9% | 43,560 | +4.2% | 0.00% | 0.0% |
| Q1 2019 | $4,678,000 | -75.6% | 41,820 | -78.0% | 0.00% | -83.3% |
| Q4 2018 | $19,200,000 | -13.1% | 190,497 | +8.9% | 0.01% | 0.0% |
| Q3 2018 | $22,101,000 | +221.2% | 174,905 | +113.3% | 0.01% | +200.0% |
| Q2 2018 | $6,881,000 | +317.3% | 81,996 | +205.9% | 0.00% | – |
| Q1 2018 | $1,649,000 | -93.3% | 26,809 | -93.7% | 0.00% | -100.0% |
| Q4 2017 | $24,770,000 | +96.9% | 424,019 | +95.6% | 0.01% | +75.0% |
| Q3 2017 | $12,580,000 | +695.2% | 216,736 | +1558.3% | 0.00% | – |
| Q2 2017 | $1,582,000 | -33.1% | 13,070 | -37.4% | 0.00% | – |
| Q1 2017 | $2,364,000 | +3.1% | 20,894 | -1.0% | 0.00% | – |
| Q4 2016 | $2,292,000 | -28.3% | 21,102 | +8.7% | 0.00% | -100.0% |
| Q3 2016 | $3,196,000 | +138.0% | 19,413 | +106.1% | 0.00% | – |
| Q2 2016 | $1,343,000 | +156.8% | 9,418 | +131.3% | 0.00% | – |
| Q1 2016 | $523,000 | -83.3% | 4,072 | -80.5% | 0.00% | -100.0% |
| Q4 2015 | $3,124,000 | -32.5% | 20,923 | -25.0% | 0.00% | -50.0% |
| Q3 2015 | $4,626,000 | -80.9% | 27,893 | -72.2% | 0.00% | -75.0% |
| Q2 2015 | $24,257,000 | -17.2% | 100,493 | -3.2% | 0.01% | -27.3% |
| Q1 2015 | $29,287,000 | +71.6% | 103,847 | -5.1% | 0.01% | +83.3% |
| Q4 2014 | $17,069,000 | -42.2% | 109,416 | -12.3% | 0.01% | -45.5% |
| Q3 2014 | $29,514,000 | +47.0% | 124,698 | +47.0% | 0.01% | +37.5% |
| Q2 2014 | $20,076,000 | -26.2% | 84,844 | +2.9% | 0.01% | -27.3% |
| Q1 2014 | $27,191,000 | +36154.7% | 82,449 | +7409.0% | 0.01% | – |
| Q4 2013 | $75,000 | – | 1,098 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |